MannKind completed the acquisition of scPharmaceuticals for $360m.

MannKind, a biopharmaceutical company, completed the acquisition of scPharmaceuticals, a clinical-stage pharmaceutical company focused on advancing cardiorenal care, for $360m. “With the close of the acquisition, MannKind now has multiple revenue lines with strong growth potential, a deepening presence in cardiometabolic care, and a commercial infrastructure ready to support the next phase of growth. This milestone accelerates our strategy to build a patient-centric company that delivers innovative therapies for chronic disease,” Michael Castagna, MannKind Corporation CEO.